AIMS: Reactive oxygen species (ROS)-mediated intracellular signalling is well described in the vasculature, yet the precise roles of ROS in paracrine signalling are not known. Studies implicate interstitial ROS hydrogen peroxide (H(2)O(2)) in vascular disease, and plasma H(2)O(2) levels in the micromolar range are detectable in animal models and humans with hypertension. Recently, H(2)O(2) was shown to cross biological membranes of non-vascular cells via aquaporin (Aqp) water channels. Previous findings suggest that H(2)O(2) activates NADPH oxidase (Nox) enzymes in vascular cells and apoptosis signal-regulating kinase 1 (Ask1) in non-vascular cells. We hypothesized that extracellular H(2)O(2) induces smooth muscle cell (SMC) hypertrophy by a mechanism involving Aqp1, Nox1, and Ask1. METHODS AND RESULTS: Treatment of rat aortic SMCs (rASMC) with exogenous H(2)O(2) resulted in a concentration-dependent increase in Nox-derived superoxide (O(2)(•-)), determined by L-012 chemiluminescence, cytochrome c and electron paramagnetic resonance. Nox1 was verified as the source of O(2)(·-) by siRNA. Aqp1 siRNA attenuated H(2)O(2) cellular entry and H(2)O(2)-induced O(2)(•-) production. H(2)O(2) treatment increased Ask1 activation and induced rASMC hypertrophy in a Nox1-dependent mechanism. Adenoviral-dominant-negative Ask1 attenuated H(2)O(2)-induced rASMC hypertrophy and adenoviral overexpression of Ask1 augmented it. CONCLUSION: Our results demonstrate for the first time that extracellular H(2)O(2), at pathophysiological concentrations, stimulates rASMC Nox1-derived O(2)(•-), subsequent Ask1 activation and SMC hypertrophy. The data demonstrate a novel pathway by which H(2)O(2) enters vascular cells via aquaporins and activates Nox, leading to hypertrophy, and provide multiple novel targets for combinatorial therapeutics development targeting hypertrophy and vascular disease.
AIMS: Reactive oxygen species (ROS)-mediated intracellular signalling is well described in the vasculature, yet the precise roles of ROS in paracrine signalling are not known. Studies implicate interstitial ROShydrogen peroxide (H(2)O(2)) in vascular disease, and plasma H(2)O(2) levels in the micromolar range are detectable in animal models and humans with hypertension. Recently, H(2)O(2) was shown to cross biological membranes of non-vascular cells via aquaporin (Aqp) water channels. Previous findings suggest that H(2)O(2) activates NADPH oxidase (Nox) enzymes in vascular cells and apoptosis signal-regulating kinase 1 (Ask1) in non-vascular cells. We hypothesized that extracellular H(2)O(2) induces smooth muscle cell (SMC) hypertrophy by a mechanism involving Aqp1, Nox1, and Ask1. METHODS AND RESULTS: Treatment of rat aortic SMCs (rASMC) with exogenous H(2)O(2) resulted in a concentration-dependent increase in Nox-derived superoxide (O(2)(•-)), determined by L-012 chemiluminescence, cytochrome c and electron paramagnetic resonance. Nox1 was verified as the source of O(2)(·-) by siRNA. Aqp1 siRNA attenuated H(2)O(2) cellular entry and H(2)O(2)-induced O(2)(•-) production. H(2)O(2) treatment increased Ask1 activation and induced rASMChypertrophy in a Nox1-dependent mechanism. Adenoviral-dominant-negative Ask1 attenuated H(2)O(2)-induced rASMChypertrophy and adenoviral overexpression of Ask1 augmented it. CONCLUSION: Our results demonstrate for the first time that extracellular H(2)O(2), at pathophysiological concentrations, stimulates rASMCNox1-derived O(2)(•-), subsequent Ask1 activation and SMC hypertrophy. The data demonstrate a novel pathway by which H(2)O(2) enters vascular cells via aquaporins and activates Nox, leading to hypertrophy, and provide multiple novel targets for combinatorial therapeutics development targeting hypertrophy and vascular disease.
Authors: Imad Al Ghouleh; Nicholas K H Khoo; Ulla G Knaus; Kathy K Griendling; Rhian M Touyz; Victor J Thannickal; Aaron Barchowsky; William M Nauseef; Eric E Kelley; Phillip M Bauer; Victor Darley-Usmar; Sruti Shiva; Eugenia Cifuentes-Pagano; Bruce A Freeman; Mark T Gladwin; Patrick J Pagano Journal: Free Radic Biol Med Date: 2011-06-14 Impact factor: 7.376
Authors: Thomas Cascino; Gabor Csanyi; Imad Al Ghouleh; Augusto C Montezano; Rhian M Touyz; Mounir J Haurani; Patrick J Pagano Journal: Antioxid Redox Signal Date: 2011-04-08 Impact factor: 8.401
Authors: Gábor Csányi; Eugenia Cifuentes-Pagano; Imad Al Ghouleh; Daniel J Ranayhossaini; Loreto Egaña; Lucia R Lopes; Heather M Jackson; Eric E Kelley; Patrick J Pagano Journal: Free Radic Biol Med Date: 2011-04-17 Impact factor: 7.376
Authors: Francis J Miller; Xi Chu; Bojana Stanic; Xin Tian; Ram V Sharma; Robin L Davisson; Fred S Lamb Journal: Antioxid Redox Signal Date: 2010-03-01 Impact factor: 8.401
Authors: Hyehun Choi; Ryan J Stark; Benjamin S Raja; Anna Dikalova; Fred S Lamb Journal: Am J Physiol Heart Circ Physiol Date: 2019-03-29 Impact factor: 4.733
Authors: Marie Billaud; Alexander W Lohman; Scott R Johnstone; Lauren A Biwer; Stephanie Mutchler; Brant E Isakson Journal: Pharmacol Rev Date: 2014-03-26 Impact factor: 25.468
Authors: Imad Al Ghouleh; Sanghamitra Sahoo; Daniel N Meijles; Jefferson H Amaral; Daniel S de Jesus; John Sembrat; Mauricio Rojas; Dmitry A Goncharov; Elena A Goncharova; Patrick J Pagano Journal: Clin Sci (Lond) Date: 2017-07-16 Impact factor: 6.124
Authors: V Montiel; E Leon Gomez; C Bouzin; H Esfahani; M Romero Perez; I Lobysheva; O Devuyst; C Dessy; J L Balligand Journal: Pflugers Arch Date: 2013-07-20 Impact factor: 3.657